Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer

Joseph G. Rajendran, David L. Schwartz, Janet O'Sullivan, Lanell M. Peterson, Patrick Ng, Jeffrey Scharnhorst, John R. Grierson, Kenneth Krohn

Research output: Contribution to journalArticle

271 Citations (Scopus)

Abstract

Purpose: Advanced head and neck cancer shows hypoxia that results in biological changes to make the tumor cells more aggressive and less responsive to treatment resulting in poor survival. [F-18] fluoromisonidazole (FMISO) positron emission tomography (PET) has the ability to noninvasively quantify regional hypoxia. We investigated the prognostic effect of pretherapy FMISO-PET on survival in head and neck cancer. Experimental Design: Seventy-three patients with head and neck cancer had pretherapy FMISO-PET and 53 also had fluorodeoxyglucose (FDG) PET under a research protocol from April 1994 to April 2004. Results: Significant hypoxia was identified in 58 patients (79%). The mean FMISO tumor/bloodmax (T/Bmax) was 1.6 and the mean hypoxic volume (HV) was 40.2 mL. There were 28 deaths in the follow-up period. Mean FDG standard uptake value (SUV)max was 10.8. The median time for follow-up was 72 weeks. In a univariate analysis, T/Bmax (P = 0.002), HV (P = 0.04), and the presence of nodes (P = 0.01) were strong independent predictors. In a multivariate analysis, including FDG SUV max, no variable was predictive at P <0.05. When FDG SUV max was removed from the model (resulting in n = 73 with 28 events), nodal status and T/Bmax (or HV) were both highly predictive (P = 0.02,0.006 for node and T/Bmax, respectively; P = 0.02 and 0.001 for node and HV, respectively). Conclusions: Pretherapy FMISO uptake shows a strong trend to be an independent prognostic measure in head and neck cancer.

Original languageEnglish (US)
Pages (from-to)5435-5441
Number of pages7
JournalClinical Cancer Research
Volume12
Issue number18
DOIs
StatePublished - Sep 15 2006
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Positron-Emission Tomography
Neoplasms
Survival
Research Design
Multivariate Analysis
Tumor Hypoxia
fluoromisonidazole
Research
Hypoxia
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. / Rajendran, Joseph G.; Schwartz, David L.; O'Sullivan, Janet; Peterson, Lanell M.; Ng, Patrick; Scharnhorst, Jeffrey; Grierson, John R.; Krohn, Kenneth.

In: Clinical Cancer Research, Vol. 12, No. 18, 15.09.2006, p. 5435-5441.

Research output: Contribution to journalArticle

Rajendran, JG, Schwartz, DL, O'Sullivan, J, Peterson, LM, Ng, P, Scharnhorst, J, Grierson, JR & Krohn, K 2006, 'Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer', Clinical Cancer Research, vol. 12, no. 18, pp. 5435-5441. https://doi.org/10.1158/1078-0432.CCR-05-1773
Rajendran, Joseph G. ; Schwartz, David L. ; O'Sullivan, Janet ; Peterson, Lanell M. ; Ng, Patrick ; Scharnhorst, Jeffrey ; Grierson, John R. ; Krohn, Kenneth. / Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 18. pp. 5435-5441.
@article{f0ca127b07d047069eb71c600d094372,
title = "Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer",
abstract = "Purpose: Advanced head and neck cancer shows hypoxia that results in biological changes to make the tumor cells more aggressive and less responsive to treatment resulting in poor survival. [F-18] fluoromisonidazole (FMISO) positron emission tomography (PET) has the ability to noninvasively quantify regional hypoxia. We investigated the prognostic effect of pretherapy FMISO-PET on survival in head and neck cancer. Experimental Design: Seventy-three patients with head and neck cancer had pretherapy FMISO-PET and 53 also had fluorodeoxyglucose (FDG) PET under a research protocol from April 1994 to April 2004. Results: Significant hypoxia was identified in 58 patients (79{\%}). The mean FMISO tumor/bloodmax (T/Bmax) was 1.6 and the mean hypoxic volume (HV) was 40.2 mL. There were 28 deaths in the follow-up period. Mean FDG standard uptake value (SUV)max was 10.8. The median time for follow-up was 72 weeks. In a univariate analysis, T/Bmax (P = 0.002), HV (P = 0.04), and the presence of nodes (P = 0.01) were strong independent predictors. In a multivariate analysis, including FDG SUV max, no variable was predictive at P <0.05. When FDG SUV max was removed from the model (resulting in n = 73 with 28 events), nodal status and T/Bmax (or HV) were both highly predictive (P = 0.02,0.006 for node and T/Bmax, respectively; P = 0.02 and 0.001 for node and HV, respectively). Conclusions: Pretherapy FMISO uptake shows a strong trend to be an independent prognostic measure in head and neck cancer.",
author = "Rajendran, {Joseph G.} and Schwartz, {David L.} and Janet O'Sullivan and Peterson, {Lanell M.} and Patrick Ng and Jeffrey Scharnhorst and Grierson, {John R.} and Kenneth Krohn",
year = "2006",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-05-1773",
language = "English (US)",
volume = "12",
pages = "5435--5441",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer

AU - Rajendran, Joseph G.

AU - Schwartz, David L.

AU - O'Sullivan, Janet

AU - Peterson, Lanell M.

AU - Ng, Patrick

AU - Scharnhorst, Jeffrey

AU - Grierson, John R.

AU - Krohn, Kenneth

PY - 2006/9/15

Y1 - 2006/9/15

N2 - Purpose: Advanced head and neck cancer shows hypoxia that results in biological changes to make the tumor cells more aggressive and less responsive to treatment resulting in poor survival. [F-18] fluoromisonidazole (FMISO) positron emission tomography (PET) has the ability to noninvasively quantify regional hypoxia. We investigated the prognostic effect of pretherapy FMISO-PET on survival in head and neck cancer. Experimental Design: Seventy-three patients with head and neck cancer had pretherapy FMISO-PET and 53 also had fluorodeoxyglucose (FDG) PET under a research protocol from April 1994 to April 2004. Results: Significant hypoxia was identified in 58 patients (79%). The mean FMISO tumor/bloodmax (T/Bmax) was 1.6 and the mean hypoxic volume (HV) was 40.2 mL. There were 28 deaths in the follow-up period. Mean FDG standard uptake value (SUV)max was 10.8. The median time for follow-up was 72 weeks. In a univariate analysis, T/Bmax (P = 0.002), HV (P = 0.04), and the presence of nodes (P = 0.01) were strong independent predictors. In a multivariate analysis, including FDG SUV max, no variable was predictive at P <0.05. When FDG SUV max was removed from the model (resulting in n = 73 with 28 events), nodal status and T/Bmax (or HV) were both highly predictive (P = 0.02,0.006 for node and T/Bmax, respectively; P = 0.02 and 0.001 for node and HV, respectively). Conclusions: Pretherapy FMISO uptake shows a strong trend to be an independent prognostic measure in head and neck cancer.

AB - Purpose: Advanced head and neck cancer shows hypoxia that results in biological changes to make the tumor cells more aggressive and less responsive to treatment resulting in poor survival. [F-18] fluoromisonidazole (FMISO) positron emission tomography (PET) has the ability to noninvasively quantify regional hypoxia. We investigated the prognostic effect of pretherapy FMISO-PET on survival in head and neck cancer. Experimental Design: Seventy-three patients with head and neck cancer had pretherapy FMISO-PET and 53 also had fluorodeoxyglucose (FDG) PET under a research protocol from April 1994 to April 2004. Results: Significant hypoxia was identified in 58 patients (79%). The mean FMISO tumor/bloodmax (T/Bmax) was 1.6 and the mean hypoxic volume (HV) was 40.2 mL. There were 28 deaths in the follow-up period. Mean FDG standard uptake value (SUV)max was 10.8. The median time for follow-up was 72 weeks. In a univariate analysis, T/Bmax (P = 0.002), HV (P = 0.04), and the presence of nodes (P = 0.01) were strong independent predictors. In a multivariate analysis, including FDG SUV max, no variable was predictive at P <0.05. When FDG SUV max was removed from the model (resulting in n = 73 with 28 events), nodal status and T/Bmax (or HV) were both highly predictive (P = 0.02,0.006 for node and T/Bmax, respectively; P = 0.02 and 0.001 for node and HV, respectively). Conclusions: Pretherapy FMISO uptake shows a strong trend to be an independent prognostic measure in head and neck cancer.

UR - http://www.scopus.com/inward/record.url?scp=33749344131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749344131&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-05-1773

DO - 10.1158/1078-0432.CCR-05-1773

M3 - Article

C2 - 17000677

AN - SCOPUS:33749344131

VL - 12

SP - 5435

EP - 5441

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -